A missed opportunity - consequences of unknown levetiracepam pharmacokinetics in a peritoneal dialysis patient.

Bahte, Svenja K; Hiss, Marcus; Lichtinghagen, Ralf; Kielstein, Jan T

Bahte, Svenja K; Hiss, Marcus; Lichtinghagen, Ralf; Kielstein, Jan T.

Affiliation

Kielstein JT; Department of Nephrology and Hypertension and Institute for Clinical Chemistry, Medical School Hannover, Carl-Neuberg-Strasse 1, Hannover 30625, Germany. kielstein@yahoo.com.

BMC Nephrol ; 15: 49, 2014 Apr 16.

Article in En | MEDLINE | ID: mdl-24739070

Subject(s)

Fatigue/chemically induced; Peritoneal Dialysis; Piracetam/analogs & derivatives; Renal Insufficiency, Chronic/metabolism; Seizures/drug therapy; Aged; Anticonvulsants/administration & dosage; Anticonvulsants/adverse effects; Anticonvulsants/pharmacokinetics; Fatigue/prevention & control; Humans; Levetiracetam; Male; Metabolic Clearance Rate; Piracetam/administration & dosage; Piracetam/adverse effects; Piracetam/pharmacokinetics; Renal Insufficiency, Chronic/complications; Renal Insufficiency, Chronic/drug therapy; Seizures/complications; Treatment Outcome

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piracetam / Seizures / Peritoneal Dialysis / Renal Insufficiency, Chronic / Fatigue Type of study: Guideline Limits: Aged / Humans / Male Language: En Journal: BMC Nephrol Journal subject: NEFROLOGIA Year: 2014 Document type: Article Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google